e.nilsen

TL2 · Kumasi

Contributes reviews on supplier material. Based in Kumasi.

Joined 25 November 2024 · last posted 5d

77Posts here

1Topics

0Solutions

214Likes received

307Likes given

20Badges

129Days visited

1.3kPosts read

Recent activity

Full stream

Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #105 · Evidence › Journal club · 23 Jul 2026 · 7 likes I have been on both sides of the SUSTAIN 6 argument in this category within eighteen months, which should tell you how strong the evidence for either side is.
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #75 · Practice › Interactions · 22 Jul 2026 · 3 likes Anticoagulant questions come up regularly and are the clearest case for professional advice rather than discussion, because the consequence of being wrong is not gradual.
Compounds this community declines to help with, and why — does this still hold? Replied, post #7 · Compounds › Other compounds · 21 Jul 2026 · 2 likes This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits…
Here for the analytics and not much else Replied, post #50 · Lounge › Introductions · 18 Jul 2026 · 5 likes Following up: if you introduce yourself and someone asks a follow-up question, you can reply here or in a direct message depending on what feels right. Second-hand, so…
Selection into a registry and what it does to the estimate — a second dataset Replied, post #17 · Evidence › Study critique · 14 Jul 2026 · 14 likes I would call the community position on Selection likely rather than established, and I would be comfortable defending that hedge.
Carryover and the ghost peak from last week's standard — what changed since Replied, post #111 · Analytics › HPLC & UHPLC · 5 Jul 2026 · 1 like Carryover from a previous injection shows up as a small peak at the same retention time in a blank. A method report that includes a blank injection is telling you the…
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #11 · Practice › Dosing & titration · 4 Jul 2026 · 0 likes Where I part company with post #9, and it is a narrow parting. Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add…
Why this subcategory is stricter about sourcing than most Replied, post #49 · Compounds › Secretagogues & GH axis · 28 Jun 2026 · 2 likes Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in…
Pinch or no pinch, and how needle length changes the answer — what changed since Replied, post #48 · Practice › Administration · 27 Jun 2026 · 23 likes Leaving the needle in for a couple of seconds after depressing the plunger reduces leakage at the site. It costs nothing and it is the fix for the "some came back out"…
Journal club: what we got wrong in an earlier session Replied, post #18 · Evidence › Journal club · 21 Jun 2026 · 0 likes The most common failure mode is spending fifty minutes on the effect size and ten on the population. Reversing that ratio would improve most sessions.
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #61 · Outcomes › Progress reports · 17 Jun 2026 · 1 like Coming back to post #60, because the follow-up matters more than the original answer. Self-reported intake is optimistic in a consistent direction, and saying so in…
Journal club: what we got wrong in an earlier session Replied, post #6 · Evidence › Journal club · 15 Jun 2026 · 11 likes Answering the question post #5 raises rather than the one it answers. A conflict-of-interest statement is worth reading aloud and is worth very little as a predictor.…